Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 48fludarabine 32Methotrexate 24blinatumomab 20fludarabine phosphate 19Dexamethasone 19Vincristine 18Whole-Body Irradiation 16Specimen Handling 16Cytarabine 16Tacrolimus 14Mycophenolic Acid 14Peripheral Blood Stem Cell Transplantation 13Melphalan 13Mercaptopurine 12Calcium Dobesilate 12merphos 11Busulfan 11Biopsy 11Magnetic Resonance Spectroscopy 10Etoposide 10Stem Cell Transplantation 9Prednisone 9Granulocyte Colony-Stimulating Factor 9Cyclosporine 9Thiotepa 8Rituximab 8Mesna 8Filgrastim 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × tisagenlecleucel × 90 days × Clear all
NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡